CD274 and neoplasm: PD-L1 small molecule inhibitors can overcome the limits of anti-PD-L1 mAbs, including poor tissue and tumor permeability, long half-life, and poor oral bioavailability, which has motivated researchers to focus on peptide and non-peptide small molecule inhibitors as viable substitutes or supplements to anti-PD-L1 mAbs 55.